Tamoxifen in the management of advanced breast carcinoma in Nigerian women.

Twenty-nine Nigerian women with advanced breast carcinoma treated with Tamoxifen (Nolvadex ICI) at a dosage of 20 mg twice daily have been reviewed. Eight of 26 evaluable patients had objective response (31%). No statistically significant association was found between response rate and menopausal status, previous chemotherapy or disease free interval. The drug was well tolerated with a low incidence of side effects. This study suggests that Tamoxifen is a useful drug in the adjuvant management of patients with advanced breast carcinoma in Nigeria.